Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 511 dose-comparison study in untreated advanced melanoma
NL-OMON47433Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of nivolumab and ipilimumab, sponsored by Bristol Myers Squibb. Started Oct 2017; status: completed.
02
Drugs
nivolumabipilimumab
Beyond the preview
Go deeper on NL-OMON47433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47433.